Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study

AIMS: Patients with pulmonary arterial hypertension associated with congenital heart disease (CHD‐PAH) after defect correction have a poor prognosis compared with other CHD‐PAH patients. Therefore, it is important that these patients are treated as early and effectively as possible. Evidence support...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur J Heart Fail
Egile Nagusiak: Beghetti, Maurice, Channick, Richard N., Chin, Kelly M., Di Scala, Lilla, Gaine, Sean, Ghofrani, Hossein‐Ardeschir, Hoeper, Marius M., Lang, Irene M., McLaughlin, Vallerie V., Preiss, Ralph, Rubin, Lewis J., Simonneau, Gérald, Sitbon, Olivier, Tapson, Victor F., Galiè, Nazzareno
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Ltd 2019
Gaiak:
Clinical Trials
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6607487/
https://ncbi.nlm.nih.gov/pubmed/30632656
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.1375
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak